Published online before print October 20, 2003, doi: 10.1161/01.HYP.0000097601.83235.F8
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Hypertension. 2003;42:962.)
© 2003 American Heart Association, Inc.
Scientific Contributions |
Suppression of 
-Melanocyte–Stimulating Hormone Secretion Is Accompanied by Salt-Sensitive Hypertension in the Rat
From the Institute of Clinical Pharmacology and Toxicology (H.M., S.A.), the Department of Medicine E (H.M.), Chaim Sheba Medical Center, Tel-Aviv University, Israel; and the Division of Nephrology (X.-P.N., M.H.H.), San Francisco General Hospital, UCSF, San Francisco, Calif.
Correspondence to Michael H. Humphreys, MD, Division of Nephrology, Box 1341, University of California San Francisco, San Francisco, CA 94143. E-mail mhhsfgh{at}itsa.ucsf.edu
-Melanocyte–stimulating hormone (-MSH) is a natriuretic peptide derived from proopiomelanocortin (POMC) in the pituitary neurointermediate lobe (NIL); its plasma concentration in rats doubles after ingestion of a high (HSD; 8% NaCl) compared with a low sodium diet (LSD; 0.07%). Because NIL function is regulated through dopaminergic pathways, we asked whether dopaminergic stimulation with bromocriptine (5 mg/kg IP daily for 1 week) or inhibition with haloperidol (5 mg/kg IP for 1 week) alters the -MSH response to a HSD. In vehicle-treated rats, plasma -MSH and NIL -MSH content on the HSD were both markedly elevated over values in rats on the LSD (P<0.001); no difference in mean arterial pressure (MAP) occurred. In haloperidol-treated rats on the LSD, both plasma -MSH and NIL -MSH content were greater than in vehicle-treated rats (P<0.05) and did not increase further on the HSD; MAP was also no different. In bromocriptine-treated rats, neither plasma -MSH nor NIL -MSH content increased on the HSD versus LSD, and MAP was markedly elevated on the HSD (132±3 versus 106±3 mm Hg, P<0.001). Intravenous infusion of -MSH (0.4 pmol/min) to bromocriptine-treated rats on the HSD restored plasma -MSH concentration to a level appropriate for the HSD and lowered MAP from 131±6 to 108±5 mm Hg (P<0.01). These results demonstrate that the increases in NIL content and plasma concentration of -MSH normally occurring during ingestion of the HSD are prevented by dopaminergic suppression of NIL function. This results in deficiency of -MSH on the HSD and is accompanied by elevated blood pressure, which is corrected by infusion of the peptide. -MSH may be an important component in the normal response to a HSD; interruption of this response leads to salt-sensitive hypertension.
Key Words: natriuretic peptides • pituitary • hypertension, sodium-dependent • dopamine
This article has been cited by other articles:
 |
|
 |
|
  X.-P. Ni, C. van Dijk, D. Pearce, and M. H. Humphreys Evidence for a noradrenergic mechanism causing hypertension and abnormal glucose metabolism in rats with relative deficiency of \#947;-melanocyte-stimulating hormone Exp Physiol, August 1, 2009; 94(8): 867 - 876. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X.-P. Ni, A. Bhargava, D. Pearce, and M. H. Humphreys Modulation by dietary sodium intake of melanocortin 3 receptor mRNA and protein abundance in the rat kidney Am J Physiol Regulatory Integrative Comp Physiol, March 1, 2006; 290(3): R560 - R567. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. W. Jones Dietary Sodium and Blood Pressure Hypertension, May 1, 2004; 43(5): 932 - 935. [Full Text] [PDF]
|
|
|
|
|
|
M. H. Humphreys {gamma}-MSH, sodium metabolism, and salt-sensitive hypertension Am J Physiol Regulatory Integrative Comp Physiol, March 1, 2004; 286(3): R417 - R430. [Abstract] [Full Text] [PDF]
|
|